ObvioHealth publicizes a groundbreaking partnership with Dedalus Group to unite actual world & medical trial knowledge

NEW YORK, June 7, 2021 /PRNewswire/ — ObvioHealth, a worldwide digital analysis group (VRO), is bringing medical trial knowledge totally into the continuum of care via a brand new strategic partnership with Dedalus Group, the main healthcare and diagnostic software program options supplier in Europe. The partnership will unite ObvioHealth’s proprietary decentralized medical trial instruments with Dedalus’s software program options, connecting the dots between medical analysis and EHR (Digital Well being File) knowledge whereas supporting healthcare suppliers from 6000+ hospitals and clinics internationally to ship care to greater than 330 million sufferers.

The preliminary stage of the partnership will enable sponsors and different analysis organizations to collaborate with HCPs who can present meta-data insights from affected person information with out transferring or revealing any precise EHR knowledge. This may allow researchers to conduct granular prognostic and predictive evaluation for improved examine design and recruitment of extra exact subpopulations of affected person cohorts, giving healthcare professionals and their sufferers the chance to contribute to and/or take part in analysis, whereas sustaining full management of their knowledge, in compliance with stringent European privateness and knowledge security rules.

“At a time when personalised medication is on the rise and the ROI on drug growth is declining, we should make analysis {dollars} work tougher,” says Ivan Jarry, CEO of ObvioHealth. “There may be large and wealthy knowledge obtainable on any variety of illness states, comorbidities and biomarkers that may inform medical trials. The mixing of medical analysis with the information that sits inside EHRs has the potential to be a recreation changer. Dedalus and ObvioHealth are enabling extra exact identification of cohorts for trials whereas additionally facilitating longitudinal analyses that may establish new indications and/or long-term impacts of sure remedies.”

“With this partnership, we’re aiming to enhance translational medication via a spectrum of choices: from decentralized trials…all the way in which to artificial trials, leveraging the complete potential of present real-world knowledge to permit for medical studying and validation of all types of therapeutical approaches,” provides Dr. Michael Dahlweid, MD, PhD, the Chief Product & Scientific Officer at Dedalus Group.

In step with the purpose of enhancing the continuum of care, the partnership can even supply researchers knowledge companies exterior the boundaries of conventional medical trials for the needs of coaching AI enabled instruments and/or creating diagnostic devices that may present deeper and/or longitudinal evaluation of sure illness states. In parallel, the collaboration will enrich healthcare supplier insights by integrating time limit medical analysis into the day by day workflow of Dedalus’s community of hospitals.

“Up till now, the medical trial atmosphere has been very separate from that of the care universe. The information from every is structured in another way and there’s no frequent language, requiring an amazing effort to extract and homogenize knowledge with suboptimal outcomes,” says Koenraad Batselier, Vice President Life Sciences at Dedalus Group. “By serving to researchers to achieve insights from the complete units of GDPR-compliant, real-world knowledge for his or her trials and giving clinicians entry to extra medical trial alternatives for his or her sufferers, we’re bringing the 2 worlds collectively. This has the potential to speed up and enhance medical trial outcomes, whereas contributing to a greater continuum of care. We’re happy to have the chance to collaborate with ObvioHealth to convey this modern platform to market.”

About ObvioHealth

ObvioHealth is an end-to-end Digital Analysis Group (VRO) that delivers a better medical trial expertise for members and higher knowledge to sponsors. The corporate developed and launched one of many first DCT apps, downloadable on smartphones, enabling individuals to take part in medical trials from the consolation of their houses. Within the four years since launch, the corporate has been awarded almost 40 research from 28 blue chip purchasers, applied in 28 international locations, in 16 totally different therapeutic areas.

For extra data, go to www.obviohealth.com

About Dedalus

Dedalus Group is the main healthcare and diagnostic software program supplier in Europe, supporting the digital transformation of 6100 hospitals and 5300 Laboratories worldwide, processing its options for greater than 330M affected person information. The corporate just lately introduced the profitable acquisition of DXC Expertise’s world healthcare data know-how (ICT) enterprise, strengthening its place as a specialist healthcare ICT firm, with one of many largest digital well being analysis and growth groups in Europe.

For extra data, go to www.dedalus.com

SOURCE ObvioHealth

Please follow and like us: